Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021

Rhea-AI Summary

Integer Holdings Corporation (NYSE: ITGR) reported a strong financial performance for Q4 and FY 2021, highlighting a 16% increase in Q4 sales to $313 million and a 14% increase in full-year sales to $1.221 billion. GAAP income from continuing operations rose by 30% in Q4, reaching $20 million, while full-year GAAP income climbed by 20% to $93 million. The company completed the acquisition of Oscor Inc. in December 2021, contributing to a total debt increase of $197 million to $828 million. Looking ahead, Integer projects sales growth of 10% to 12% for 2022.

Positive

• Q4 sales increased 16% to $313 million.
• Full-year sales rose 14% to $1.221 billion.
• GAAP income from continuing operations increased 30% in Q4 to $20 million.
• Adjusted net income surged 41% in Q4 to $33 million.
• Completed acquisition of Oscor Inc., enhancing market position.
• Generated $157 million in cash flow from operations for the year.

Negative

• Total debt increased by $197 million to $828 million due to the Oscor acquisition.
• Sales in Advanced Surgical, Orthopedics & Portable Medical declined by 10% year-over-year.

~ Strong 4Q and Full Year sales and profit increase versus last year ~
~ Completed acquisition of Oscor Inc. ~
~ Generated $157 million cash flow from operations in the full year ~

PLANO, Texas, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and twelve months ended December 31, 2021. Unless otherwise stated, all results and comparisons are from continuing operations and include the results of operations from Oscor for the period December 1, 2021 through December 31, 2021.

Fourth Quarter 2021 Financial Results (compared to fourth quarter 2020, except as noted)

• Sales increased 16% to $313 million.
• GAAP income from continuing operations increased $5 million to $20 million, an increase of 30%. Adjusted net income increased $10 million to $33 million, an increase of 41%.
• GAAP operating income increased $1 million to $29 million, an increase of 4%. Adjusted operating income increased $6 million to $44 million, an increase of 16%.
• GAAP diluted EPS from continuing operations increased $0.13 per share to $0.60 per share, an increase of 28%. Adjusted EPS increased $0.28 per share to $0.99 per share, an increase of 39%.
• Adjusted EBITDA increased $9 million to $58 million, an increase of 19%.
• In December, completed acquisition of Oscor, a private medical device company headquartered in Florida with significant manufacturing operations in the Dominican Republic.
• From the end of the third quarter 2021, total debt increased $197 million to $828 million and net total debt increased $206 million to $818 million due to the Oscor acquisition.
  

Full Year 2021 Financial Results (compared to full year 2020)

• Sales increased 14% to $1.221 billion.
• GAAP income from continuing operations increased $16 million to $93 million, an increase of 20%. Adjusted net income increased $44 million to $136 million, an increase of 48%.
• GAAP operating income increased $15 million to $136 million, an increase of 13%. Adjusted operating income increased $43 million to $187 million, an increase of 30%.
• GAAP diluted EPS from continuing operations increased $0.47 per share to $2.80 per share, an increase of 20%. Adjusted EPS increased $1.31 per share to $4.08 per share, an increase of 47%.
• Adjusted EBITDA increased $53 million to $243 million, an increase of 28%.
• Generated $157 million of cash flow from operating activities.

“Integer delivered strong year-over-year financial results in the fourth quarter and full year 2021 despite a challenging labor and supply chain environment. Looking forward to 2022, we expect our year-over-year sales and profit growth to increase throughout the year. The growth will come from the execution of our strategy as well as the integration of Oscor, which is well underway,” said Joseph Dziedzic, Integer’s president and CEO.

Mr. Dziedzic continued, “During 2021 we protected our associates, delivered for our customers and patients, strengthened our culture, and remained focused on executing our strategy. Integer’s unique position is enabling us to serve our customers through all phases of their products’ lifecycles. Our customers are rewarding us with more development programs in high-growth markets, in support of their product roadmaps. We are confident that our structured and disciplined product line strategy process combined with our targeted investments in high-growth markets will drive sustained above-market growth.”

Discussion of Product Line Fourth Quarter and Full Year Sales

• Cardio & Vascular sales increased 19% in the fourth quarter 2021 compared to fourth quarter 2020 and full year sales increased 10% year-over-year. Strong double-digit year-over-year sales increases in the fourth quarter across all C&V markets, with particular strength in the neurovascular market, despite end market demand fluctuations and supply chain constraints. Full year sales exceeded 2019 pre-pandemic level, with neurovascular and structural heart both growing double-digits compared to 2019.
• Cardiac & Neuromodulation sales increased 19% in the fourth quarter 2021 compared to fourth quarter 2020 and full year sales increased 29% year-over-year. Strong year-over-year fourth quarter sales increases across all markets, despite end market demand fluctuations and supply chain constraints, with both Cardiac Rhythm Management and Neuromodulation increasing double-digits. Neuromodulation full year sales exceeded pre-pandemic levels and grew high single-digits compared to 2019 when normalized to exclude $17 million of 2019 sales to Nuvectra. Nuvectra filed for bankruptcy in the fourth quarter of 2019.
• Advanced Surgical, Orthopedics & Portable Medical includes sales under supply agreement to the acquirer of our divested AS&O product line. Fourth quarter 2021 sales declined 10% compared to fourth quarter 2020 and full year sales decreased 10% year-over-year. Sales decline in the fourth quarter driven by reductions in demand for COVID-related ventilator and patient monitoring components. Full year sales reflect double-digit decline in Advanced Surgical and Orthopedics, the divested product line currently under supply agreement, and low single-digit decline in Portable Medical driven by lower demand for COVID-related ventilators and patient monitoring components.
• Electrochem sales increased 34% in the fourth quarter 2021 compared to fourth quarter 2020 and full year sales increased 8% year-over-year. Strong fourth quarter growth reflects continued energy market recovery. Full year sales growth reflects moving from a period of energy market contraction to recovery beginning in the second quarter of 2021.

2022 Outlook^(a)

• Sales growth projected to be 10% to 12%, organic growth of 5% - 7%.
  • Expect 1Q22 sales to be similar to 4Q21, constrained by COVID surge impact on labor and supply chain
  • Expect 2Q22 sales to be better than 1Q22 from reduced impact of January’s COVID surge and supply chain volatility
  • Anticipate strong second-half sales growth from improved labor, supply chain, and new product introductions
• Operating income guidance assumes supply chain and labor constraints improve in the second half.
• Expect free cash flow to be in the range of $90 to $105 million.

(dollars in millions, except per share amounts)

		GAAP				Non-GAAP(b)
		As Reported		Change		Adjusted		Change
Sales		$1,340 to $1,365		10% to 12%		$1,340 to $1,365		10% to 12%
Operating income		$132 to $144		(3)% to 6%		$201 to $213		7% to 14%
EBITDA		N/A		N/A		$270 to $282		11% to 16%
Net income		$91 to $101		(2)% to 9%		$146 to $156		7% to 15%
Earnings per Diluted Share		$2.72 to $3.02		(3)% to 8%		$4.35 to $4.65		7% to 14%

^(a) Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for Adjusted operating income, Adjusted EBITDA, Adjusted net income, organic sales growth and Adjusted Earnings per Share (“EPS”), all from continuing operations, and free cash flow, included in our “2022 Outlook” above, and Adjusted interest expense and Adjusted effective tax rate below, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.

^(b) Adjusted operating income for 2022 is expected to consist of GAAP operating income, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions and severance, totaling approximately $69 million, pre-tax. Adjusted net income and Adjusted EPS for 2022 are expected to consist of GAAP net income and diluted EPS, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions, severance, gains and losses on equity investments and loss on extinguishment of debt totaling approximately $70 million, pre-tax. The after-tax impact of these items is estimated to be approximately $55 million, or approximately $1.63 per diluted share.

Adjusted EBITDA is expected to consist of Adjusted net income, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $124 to $126 million.

Supplemental Financial Information
(dollars in millions)

	2022 Outlook		2021 Actual
Capital expenditures, net	$65 - $75		$53
Depreciation and amortization	$90 - $100		$81
Stock-based compensation	$18 - $21		$16
Other operating expense	$10 - $15		$8
Adjusted interest expense(a)	$24 - $28		$28
Adjusted effective tax rate(b)	16.0% - 17.5%		15%
Cash tax payments	$15 - $20		$20

^(a) Adjusted interest expense refers to our expected full-year GAAP interest expense, expected to range from $25 million to $29 million for 2022, adjusted to remove the full-year impact of charges associated with the write-off of deferred issuance costs and unamortized discounts (loss on extinguishment of debt) included in GAAP interest expense.

^(b) Adjusted effective tax rate refers to our full-year GAAP effective tax rate, expected to range from 14.0% to 15.5% for 2022, adjusted to reflect the full-year impact of the items that are excluded in providing adjusted net income and certain other identified items.

Summary Financial Results
(dollars in thousands, except per share data)

	Three Months Ended December 31,
		2021			2020		Change
EBITDA from continuing operations(a)	$	48,529		$	47,540		2.1	%
Operating income	$	28,663		$	27,593		3.9	%
Income from continuing operations	$	20,001		$	15,427		29.6	%
Diluted EPS from continuing operations	$	0.60		$	0.47		27.7	%
Adjusted EBITDA(a)	$	58,469		$	49,236		18.8	%
Adjusted operating income(a)	$	44,019		$	37,975		15.9	%
Adjusted net income(a)	$	33,057		$	23,424		41.1	%
Adjusted EPS(a)	$	0.99		$	0.71		39.4	%
	Year Ended December 31,
		2021			2020		Change
EBITDA from continuing operations(a)	$	214,060		$	203,751		5.1	%
Operating income	$	135,711		$	120,612		12.5	%
Income from continuing operations	$	93,020		$	77,258		20.4	%
Diluted EPS from continuing operations	$	2.80		$	2.33		20.2	%
Adjusted EBITDA(a)	$	242,983		$	189,616		28.1	%
Adjusted operating income(a)	$	187,175		$	143,782		30.2	%
Adjusted net income(a)	$	135,550		$	91,849		47.6	%
Adjusted EPS(a)	$	4.08		$	2.77		47.3	%

^(a) EBITDA from continuing operations, Adjusted EBITDA, Adjusted operating income, Adjusted net income, and Adjusted EPS are Non-GAAP financial measures. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A, B and C at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

Summary Product Line Results
(dollars in thousands)

	Three Months Ended December 31,
		2021			2020		Change			Organic Change(a)
Medical Sales
Cardio & Vascular	$	163,381		$	137,063		19.2	%		17.6	%
Cardiac & Neuromodulation		111,869			93,838		19.2	%		17.3	%
Advanced Surgical, Orthopedics & Portable Medical		26,664			29,747		(10.4)	%		(10.4)	%
Total Medical Sales		301,914			260,648		15.8	%		14.3	%
Non-Medical Sales		11,101			8,311		33.6	%		33.6	%
Total Sales	$	313,015		$	268,959		16.4	%		14.9	%
	Year Ended December 31,
		2021			2020		Change			Organic Change(a)
Medical Sales
Cardio & Vascular	$	626,013		$	569,948		9.8	%		9.0	%
Cardiac & Neuromodulation		446,569			346,242		29.0	%		28.5	%
Advanced Surgical, Orthopedics & Portable Medical		110,044			121,788		(9.6)	%		(9.6)	%
Total Medical Sales		1,182,626			1,037,978		13.9	%		13.3	%
Non-Medical Sales		38,453			35,464		8.4	%		8.4	%
Total Sales	$	1,221,079		$	1,073,442		13.8	%		13.2	%

^(a) Organic sales change is a Non-GAAP financial measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.

Conference Call Information
The Company will host a conference call on Thursday, February 17, 2022, at 8 a.m. CT / 9 a.m. ET to discuss these results. The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (888) 330-3567 (U.S.) or (646) 960-0842 (outside U.S.) and the conference ID is 9252310. The call will be archived on the Company’s website. An earnings call slide presentation containing supplemental information about the Company’s results will be posted to our website at investor.integer.net prior to the conference call and will be referenced during the conference call.

From time to time, the Company posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.

About Integer^®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical^®, Lake Region Medical^® and Electrochem^®. Additional information is available at www.integer.net.

Contact Information
Tony Borowicz
SVP, Investor Relations
716.759.5809
tony.borowicz@integer.net

Notes Regarding Non-GAAP Financial Information
In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and organic sales change rates, all from continuing operations. Adjusted net income and adjusted EPS consist of GAAP amounts from continuing operations adjusted for the following to the extent occurring during the period: (i) acquisition and integration related expenses, including fair value adjustments to contingent consideration resulting from acquisitions, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain legal expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) (gain) loss on equity investments, (ix) extinguishment of debt charges, (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted net income by diluted weighted average shares outstanding. EBITDA is calculated by adding back interest expense, provision (benefit) for income taxes from continuing operations, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA plus adding back stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (x) and (xi). Adjusted operating income consists of operating income from continuing operations adjusted for the same items listed above except for items (viii), (ix), (x) and (xi).

Organic sales change is reported sales growth adjusted for the impact of foreign currency and the contribution of acquisitions. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue, and exclude the amount of sales acquired or divested during the period from the current/previous period amounts, respectively.

We believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted operating income, and organic sales change rates, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt, free cash flow and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters. Free cash flow is defined as Net cash provided by operating activities (as stated in our Condensed Consolidated Statements of Cash Flows) reduced by capital expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from the sale of PP&E).

Forward-Looking Statements
Some of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to recovery from the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy, including completion and integration of current or future acquisition targets; projected capital spending; and other events, conditions or developments that will or may occur in the future. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “projects,” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors and other risks and uncertainties that arise from time to time are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC and include the following:

• operational risks, such as the duration, scope and impact of the COVID-19 pandemic, including the evolving health, economic, social and governmental environments and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; interruptions in our manufacturing operations; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; our dependence upon our senior management team and technical personnel; and global climate change and the emphasis on ESG matters by various stakeholders;
• strategic risks, such as the intense competition we face and our ability to successfully market our products; our ability to respond to changes in technology; our ability to develop new products and expand into new geographic and product markets; and our ability to successfully identify, make and integrate acquisitions to expand and develop our business in accordance with expectations;
• financial risks, such as our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions; financial and market risks related to our international operations and sales; our complex international tax profile; and our ability to realize the full value of our intangible assets; and
• legal and compliance risks, such as regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability or intellectual property claims; our ability to protect our intellectual property and proprietary rights; our ability and the cost to comply with environmental regulations; our ability to comply with customer-driven policies and third party standards or certification requirements; our ability to obtain necessary licenses for new technologies; legal and regulatory risks from our international operations; and the fact that the healthcare industry is highly regulated and subject to various regulatory changes;

Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Condensed Consolidated Balance Sheets - Unaudited
(in thousands)
	December 31, 2021			December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents	$	17,885		$	49,206
Accounts receivable, net		182,310			156,207
Inventories		155,699			149,323
Refundable income taxes		4,735			2,087
Contract assets		64,743			40,218
Prepaid expenses and other current assets		27,610			15,896
Total current assets		452,982			412,937
Property, plant and equipment, net		277,099			253,964
Goodwill		924,704			859,442
Other intangible assets, net		807,810			757,224
Deferred income taxes		5,711			4,398
Operating lease assets		70,053			45,153
Other long-term assets		43,856			38,739
Total assets	$	2,582,215		$	2,371,857
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	$	15,250		$	37,500
Accounts payable		76,859			51,570
Income taxes payable		725			1,847
Operating lease liabilities		9,862			8,431
Accrued expenses and other current liabilities		56,933			56,843
Total current liabilities		159,629			156,191
Long-term debt		812,876			693,758
Deferred income taxes		171,505			182,304
Operating lease liabilities		59,767			37,861
Other long-term liabilities		23,741			30,688
Total liabilities		1,227,518			1,100,802
Stockholders’ equity:
Common stock		33			33
Additional paid-in capital		713,150			700,814
Retained earnings		614,324			517,516
Accumulated other comprehensive income		27,190			52,692
Total stockholders’ equity		1,354,697			1,271,055
Total liabilities and stockholders’ equity	$	2,582,215		$	2,371,857

Condensed Consolidated Statements of Operations - Unaudited
(in thousands except per share data)
	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Sales	$	313,015			$	268,959			$	1,221,079			$	1,073,442
Cost of sales		231,149				195,750				884,109				787,735
Gross profit		81,866				73,209				336,970				285,707
Operating expenses:
Selling, general and administrative (SG&A)		36,268				35,037				141,418				109,006
Research, development and engineering		12,736				10,589				51,985				48,468
Other operating expenses (OOE)		4,199				(10	)			7,856				7,621
Total operating expenses		53,203				45,616				201,259				165,095
Operating income		28,663				27,593				135,711				120,612
Interest expense		5,511				9,218				31,628				38,220
(Gain) loss on equity investments, net		1,276				(1,383	)			3,143				(5,337	)
Other (income) loss, net		(252	)			1,755				(123	)			1,522
Income from continuing operations before income taxes		22,128				18,003				101,063				86,207
Provision for income taxes		2,127				2,576				8,043				8,949
Income from continuing operations	$	20,001			$	15,427			$	93,020			$	77,258
Discontinued operations:
Income from discontinued operations before taxes		4,931				—				4,931				—
Provision for income taxes		1,143				—				1,143				—
Income from discontinued operations	$	3,788			$	—			$	3,788			$	—
Net income	$	23,789			$	15,427			$	96,808			$	77,258
Basic earnings per share:
Income from continuing operations	$	0.61			$	0.47			$	2.82			$	2.35
Income from discontinued operations	$	0.11			$	—			$	0.11			$	—
Basic earnings per share	$	0.72			$	0.47			$	2.93			$	2.35
Diluted earnings per share:
Income from continuing operations	$	0.60			$	0.47			$	2.80			$	2.33
Income from discontinued operations	$	0.11			$	—			$	0.11			$	—
Diluted earnings per share	$	0.71			$	0.47			$	2.91			$	2.33
Weighted average shares outstanding:
Basic		33,023				32,880				32,993				32,845
Diluted		33,280				33,129				33,258				33,113

Condensed Consolidated Statements of Cash Flows(a) - Unaudited
(in thousands)
	Year Ended December 31,
		2021				2020
Cash flows from operating activities:
Net income	$	96,808			$	77,258
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		81,369				79,324
Debt related charges included in interest expense		6,954				4,774
Stock-based compensation		16,185				9,163
Non-cash (gains) charges related to customer bankruptcy		(348	)			554
Non-cash lease expense		8,235				7,810
Non-cash (gain) loss on equity investments		3,143				(5,337	)
Contingent consideration fair value adjustment		133				(2,000	)
Other non-cash losses		2,202				600
Deferred income taxes		(10,270	)			(6,966	)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable		(17,539	)			38,153
Inventories		4,700				18,441
Prepaid expenses and other assets		(2,409	)			(864	)
Contract assets		(24,923	)			(15,451	)
Accounts payable		19,525				(9,055	)
Accrued expenses and other liabilities		(22,984	)			(10,721	)
Income taxes payable		(4,115	)			(4,342	)
Net cash provided by operating activities		156,666				181,341
Cash flows from investing activities:
Acquisition of property, plant and equipment		(53,463	)			(46,832	)
Purchase of intangible asset		—				(4,607	)
Proceeds from sale of property, plant and equipment		443				82
Acquisitions, net		(217,978	)			(5,219	)
Net cash used in investing activities		(270,998	)			(56,576	)
Cash flows from financing activities:
Principal payments of term loans		(741,786	)			(87,500	)
Proceeds from issuance of term loans		818,250				—
Proceeds from revolving credit facility		82,300				185,000
Payments of revolving credit facility		(63,000	)			(185,000	)
Proceeds from the exercise of stock options		743				3,263
Payment of debt issuance costs		(8,139	)			(515	)
Tax withholdings related to net share settlements of restricted stock unit awards		(4,592	)			(3,820	)
Contingent consideration payments		(1,621	)			—
Principal payments on finance leases		(169	)			(6	)
Net cash provided by (used in) financing activities		81,986				(88,578	)
Effect of foreign currency exchange rates on cash and cash equivalents		1,025				(516	)
Net increase (decrease) in cash and cash equivalents		(31,321	)			35,671
Cash and cash equivalents, beginning of year		49,206				13,535
Cash and cash equivalents, end of year	$	17,885			$	49,206

^(a) The Condensed Consolidated Statements of Cash Flows - Unaudited includes cash flows related to discontinued operations.

Reconciliations of Non-GAAP Financial Measures from Continuing Operations
Table A: Income from Continuing Operations and Diluted EPS Reconciliations
(dollars in thousands, except per share data)

	Three Months Ended December 31,
		2021												2020
	Pre-Tax				Net of Tax				Per Diluted Share				Pre-Tax				Net of Tax				Per Diluted Share
Income from continuing operations (GAAP)	$	22,128			$	20,001			$	0.60			$	18,003			$	15,427			$	0.47
Adjustments(a):
Amortization of intangibles		10,524				8,323				0.25				10,237				8,095				0.24
Certain legal expenses (SG&A)(b)		175				139				—				139				111				—
Other operating expenses (OOE)(c)		4,199				3,332				0.10				(10	)			235				0.01
(Gain) loss on equity investments		1,276				1,008				0.03				(1,383	)			(1,093	)			(0.03	)
Loss on extinguishment of debt		—				—				—				550				435				0.01
Medical device regulations (COS)(d)		270				214				0.01				—				—				—
Customer bankruptcy(e)		(113	)			(89	)			—				16				13				—
Inventory step-up amortization (COS)		301				266				0.01				—				—				—
Tax adjustments(f)		—				(137	)			—				—				201				0.01
Adjusted net income (Non-GAAP)	$	38,760			$	33,057			$	0.99			$	27,552			$	23,424			$	0.71
Diluted weighted average shares for adjusted EPS						33,280												33,129
	Year Ended December 31,
		2021												2020
	Pre-Tax				Net of Tax				Per Diluted Share				Pre-Tax				Net of Tax				Per Diluted Share
Income from continuing operations (GAAP)	$	101,063			$	93,020			$	2.80			$	86,207			$	77,258			$	2.33
Adjustments(a):
Amortization of intangibles		41,597				32,898				0.99				41,131				32,520				0.98
Certain legal expenses (gains) (SG&A)(b)		1,454				1,149				0.03				(26,811	)			(21,180	)			(0.64	)
Other operating expenses (OOE)(c)		7,856				6,178				0.19				7,621				6,177				0.19
(Gain) loss on equity investments		3,143				2,483				0.07				(5,337	)			(4,216	)			(0.13	)
Loss on extinguishment of debt		3,774				2,981				0.09				550				435				0.01
Medical device regulations (COS)(d)		744				588				0.02				—				—				—
Customer bankruptcy(e)		(488	)			(385	)			(0.01	)			1,229				971				0.03
Inventory step-up amortization (COS)		301				266				0.01				—				—				—
Tax adjustments(f)		—				(3,628	)			(0.11	)			—				(116	)			—
Adjusted net income (Non-GAAP)	$	159,444			$	135,550			$	4.08			$	104,590			$	91,849			$	2.77
Diluted weighted average shares for adjusted EPS						33,258												33,113

^(a) The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

^(b) Expenses associated with non-ordinary course legal matters. The full year 2020 also include a net gain of $28.2 million recorded during the third quarter of 2020 in connection with the resolution of the AVX Corporation patent litigation matter.

^(c) OOE includes acquisition and integration related expenses, facility consolidation, optimization, manufacturing transfer and system integration charges, asset write-down and disposition charges, charges in connection with corporate realignments or a reduction in force, unusual or infrequently occurring items. OOE for the fourth quarter and full year 2021 includes $2.0 million of acquisition costs related to the acquisition of Oscor. OOE for the fourth quarter and full year 2020 includes a $1.5 million adjustment to reduce the fair value of acquisition-related contingent consideration liabilities.

^(d) The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.

^(e) In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”). The 2021 amounts are predominantly due to favorable settlements on supplier purchase order termination clauses and benefits recognized from the utilization of previously reserved inventory and the 2020 amounts primarily consist of charges related to inventory recorded in cost of sales in our consolidated statements of operations.

^(f) Discrete tax benefits predominately related to the reversal of previously unrecognized tax benefits resulting from the effective settlement of tax audits and the utilization of acquired foreign tax credits during the periods presented.

Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.

Table B: Adjusted Operating Income Reconciliations
(in thousands)

	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Operating income (GAAP)	$	28,663			$	27,593			$	135,711			$	120,612
Adjustments:
Amortization of intangibles		10,524				10,237				41,597				41,131
Certain legal expenses (gains)		175				139				1,454				(26,811	)
Other operating expenses		4,199				(10	)			7,856				7,621
Medical device regulations		270				—				744				—
Customer bankruptcy		(113	)			16				(488	)			1,229
Inventory step-up amortization		301				—				301				—
Adjusted operating income (Non-GAAP)	$	44,019			$	37,975			$	187,175			$	143,782

Table C: EBITDA Reconciliations
(in thousands)

	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Income from continuing operations (GAAP)	$	20,001			$	15,427			$	93,020			$	77,258
Interest expense		5,511				9,218				31,628				38,220
Provision for income taxes		2,127				2,576				8,043				8,949
Depreciation		10,366				10,082				39,772				38,193
Amortization of intangibles		10,524				10,237				41,597				41,131
EBITDA from continuing operations (Non-GAAP)		48,529				47,540				214,060				203,751
Certain legal expenses (gains)		175				139				1,454				(26,811	)
Stock-based compensation (excluding OOE)		3,832				2,934				15,913				9,163
Other operating expenses (OOE)		4,199				(10	)			7,856				7,621
(Gain) loss on equity investments		1,276				(1,383	)			3,143				(5,337	)
Medical device regulations		270				—				744				—
Customer bankruptcy		(113	)			16				(488	)			1,229
Inventory step-up amortization		301				—				301				—
Adjusted EBITDA (Non-GAAP)	$	58,469			$	49,236			$	242,983			$	189,616

Table D: Organic Sales Change Reconciliation (% Change)

	GAAP Reported Growth			Impact of Acquisitions and Foreign Currency(a)			Non-GAAP Organic Change
Quarter over Quarter Change (4Q 2021 vs. 4Q 2020)
Medical Sales
Cardio & Vascular	19.2%			(1.6)%			17.6%
Cardiac & Neuromodulation	19.2%			(1.9)%			17.3%
Advanced Surgical, Orthopedics & Portable Medical	(10.4)%			—			(10.4)%
Total Medical Sales	15.8%			(1.5)%			14.3%
Non-Medical Sales	33.6%			—			33.6%
Total Sales	16.4%			(1.5)%			14.9%
Year over Year Change (2021 vs. 2020)
Medical Sales
Cardio & Vascular	9.8%			(0.8)%			9.0%
Cardiac & Neuromodulation	29.0%			(0.5)%			28.5%
Advanced Surgical, Orthopedics & Portable Medical	(9.6)%			—			(9.6)%
Total Medical Sales	13.9%			(0.6)%			13.3%
Non-Medical Sales	8.4%			—			8.4%
Total Sales	13.8%			(0.6)%			13.2%

^(a) Fourth quarter and full year 2021 and 2020 sales have been adjusted to exclude the contribution of business acquisitions and foreign currency exchange rate fluctuations.

Table E: Net Total Debt Reconciliation
(in thousands)

	December 31, 2021			October 1, 2021			December 31, 2020
Total debt		828,126			630,655			731,258
Add: Unamortized discount and deferred debt issuance costs		7,361			6,645			6,715
Total principal amount of debt outstanding		835,487			637,300			737,973
LESS: Cash and cash equivalents		17,885			25,472			49,206
Net Total Debt (Non-GAAP)	$	817,602		$	611,828		$	688,767

 

FAQ

What were Integer's Q4 2021 sales results for ITGR?

Integer reported a 16% increase in Q4 2021 sales, totaling $313 million.

How did Integer's full-year 2021 performance compare to 2020?

For the full year 2021, Integer achieved a 14% sales increase, reaching $1.221 billion.

What is Integer's outlook for sales growth in 2022?

Integer projects a sales growth of 10% to 12% for 2022.

What impact did the acquisition of Oscor Inc. have on Integer's debt?

Integer's total debt increased by $197 million to $828 million post-acquisition.

How much cash flow did Integer generate from operations in 2021?

Integer generated $157 million in cash flow from operations for the full year 2021.